Literature DB >> 3539884

Serum stability of 67Cu chelates: comparison with 111In and 57Co.

W C Cole, S J DeNardo, C F Meares, M J McCall, G L DeNardo, A L Epstein, H A O'Brien, M K Moi.   

Abstract

Simple chelates and chelate conjugated monoclonal antibodies labeled with 111In, 57Co and 67Cu demonstrate marked differences in stability when exposed to a serum environment. Among these radiometals, on DTPA, the order of stability is 111In greater than 57Co much greater than 67Cu. On benzyl-EDTA, the order of stability is 111In congruent to 57Co much greater than 67Cu. Among those investigated, the only serum stable 67Cu chelate found was 67Cu-TETA. The order of stability observed for 57Co vs 67Cu is contrary to published equilibrium constants. These in vitro studies suggest that the in vivo behavior of metal chelates exposed to a complex molecular environment may not be predicted by classically determined equilibrium constants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3539884     DOI: 10.1016/0883-2897(86)90011-5

Source DB:  PubMed          Journal:  Int J Rad Appl Instrum B        ISSN: 0883-2897


  13 in total

1.  Comparison of (64)Cu-complexing bifunctional chelators for radioimmunoconjugation: labeling efficiency, specific activity, and in vitro/in vivo stability.

Authors:  Maggie S Cooper; Michelle T Ma; Kavitha Sunassee; Karen P Shaw; Jennifer D Williams; Rowena L Paul; Paul S Donnelly; Philip J Blower
Journal:  Bioconjug Chem       Date:  2012-04-13       Impact factor: 4.774

2.  Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody.

Authors:  Jason L J Dearling; Stephan D Voss; Patricia Dunning; Erin Snay; Frederic Fahey; Suzanne V Smith; James S Huston; Claude F Meares; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

3.  In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas.

Authors:  Senthil R Kumar; Fabio A Gallazzi; Riccardo Ferdani; Carolyn J Anderson; Thomas P Quinn; Susan L Deutscher
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

Review 4.  The development of copper radiopharmaceuticals for imaging and therapy.

Authors:  Monica Shokeen; Thaddeus J Wadas
Journal:  Med Chem       Date:  2011-09       Impact factor: 2.745

5.  Copper-64 radiolabeling and biological evaluation of bifunctional chelators for radiopharmaceutical development.

Authors:  Ravindra A De Silva; Sandeep Jain; Kimberly A Lears; Hyun-Soon Chong; Chi Soo Kang; Xiang Sun; Buck E Rogers
Journal:  Nucl Med Biol       Date:  2012-06-27       Impact factor: 2.408

6.  Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).

Authors:  Monica Shokeen; Carolyn J Anderson
Journal:  Acc Chem Res       Date:  2009-07-21       Impact factor: 22.384

7.  Cyclam-based polymeric copper chelators for gene delivery and potential PET imaging.

Authors:  Jing Li; Yu Zhu; Stuart T Hazeldine; Steven M Firestine; David Oupický
Journal:  Biomacromolecules       Date:  2012-09-25       Impact factor: 6.988

8.  In vitro and in vivo effects of diethylene triamine penta-acetic acid on the distribution of indium-111 monoclonal antibody metabolism.

Authors:  Y Kimura; T Fujii; K Ochi; A Akamune; K Hamamoto
Journal:  Eur J Nucl Med       Date:  1992

9.  H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.

Authors:  Gwendolyn A Bailey; Eric W Price; Brian M Zeglis; Cara L Ferreira; Eszter Boros; Michael J Lacasse; Brian O Patrick; Jason S Lewis; Michael J Adam; Chris Orvig
Journal:  Inorg Chem       Date:  2012-10-29       Impact factor: 5.165

Review 10.  Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges.

Authors:  Tapan K Nayak; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2009-05-20       Impact factor: 4.774

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.